HuMax-CD4 (zanolimumab) / Emergent Biosolutions - LARVOL DELTA

COMPARATIVE EFFICACY OF THERAPEUTIC APPROACHES IN RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS (EHA 2025) - "This meta-analysis evaluates the efficacy of various therapies for RR-PTCL, including Epigenetic modifiers (HDIs, DNA methyltransferase inhibitors, EZH1/2 inhibitors), Small molecule inhibitors (targeting PI3K/AKT/mTOR, JAK/STAT, ALK, aurora kinase, farnesyl transferase), Combination therapies (various multi-class drug combinations), Pralatrexate-based regimens, monoclonal antibodies (e.g., Pembrolizumab, Alemtuzumab, Zanolimumab, etc.) and Others (Acimtamig, CAR T-cell therapy, etc.). This analysis suggests that combination therapies had the highest response rates, with SMI and pralatrexate-based therapies showing the longest OS. Other cytotoxic chemotherapy-based regimens had the lowest effectiveness, which suggests that combined targeted no-cytotoxic treatment regimens should be further studied in R/R PTCL. Outcomes continue to be poor, and clinical trials with novel treatment strategies should be prioritized"

Retrospective data • Review • Hematological Malignancies • Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • EZH2